From the Editor

Jun 01, 2010
Pharmaceutical Executive
Innovation in industry has always required a strong internal champion; the danger is a process led by the risk-adverse and externally-driven stakeholder consensus called "death by faint praise." Is this really what we mean by "bold partnerships?"
May 01, 2010
Pharmaceutical Executive
Cash-rich Big Pharmas are hedging their bets to cover both segments under the rubric of "diversification." If it sticks to the wall, then buy it.
Apr 01, 2010
Pharmaceutical Executive
Success in this harsh climate depends on seeing business through the eye of the customer
Mar 01, 2010
Pharmaceutical Executive
Is it possible to remain commercially relevant just as a developer and distributor of drugs? Are there equivalent profits in a larger set of commitments?
Feb 01, 2010
Pharmaceutical Executive
Innovation won't happen until the industry is ready to sit down and make a big change.
Jan 01, 2010
Pharmaceutical Executive
Pharma must get its definitions right to be successful in the new decade.
Dec 01, 2009
Pharmaceutical Executive
The fight against cancer may be the litmus test for how regulation and private investment work together to address the disease burden.
Nov 01, 2009
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Despite its success as a proponent of reform, the drug industry, whose main offering is a product easily siloed against other health services, remains vulnerable.
Oct 01, 2009
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Governments and payers don't see that innovation covers everything from invention to building market share. Scant attention is paid to the critical "back end" of the innovation cycle.
Sep 01, 2009
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Mastery of internal factors can mean the difference between thriving and failing in an environment where industry is a price taker, not a price setter.
native1_300x100
lorem ipsum